Greeting
The 14th JBF Symposium will be held from March 1 (Wed) to 3 (Fri), 2023 at Tower Hall Funabori in Tokyo. We plan to conduct the event in a hybrid format and have prepared a web participation option for those who have difficulty visiting the venue. As changes in COVID-19 infections are still unforeseeable, we may change the format of the meeting, giving top priority to safety by keeping a close eye on future situations.
Under the global spread of the COVID-19 pandemic, drugs, vaccines and test kits have been developed and many people have been saved. It is no exaggeration to say that it would not have been realized without the technology and development of bioanalysis. Bioanalysis will become increasingly important in order to deliver a variety of treatments and prophylaxis options to people around the world more quickly and we, and everyone involved in bioanalysis, will continue to take on challenges in order to respond to new modalities and development strategies.
In order to achieve our common purpose, we would like the symposium to be a place where people from various areas, such as government, academia, pharmaceutical companies, CROs, and device manufacturers can learn and collaborate together. That is why we decided the theme of the event will be "BRINGING TOGETHER ~ The Expertise of Bioanalysis". The JBF Steering Committee members are also working together for preparation of the symposium with our best ability to “bring together” the expertise, skills and experiences related to bioanalysis that are useful to you, to “bring together” people to be connected and also hopefully to "bring together" participants in a face-to-face symposium for providing a more meaningful time and participation.
The ICH M10 Guidelines reached Step 4 in May this year, and we have finally entered the implementation stage. In this event, we will set up an ICH M10 session and are planning that session can discuss a smoother implementation collaborating with bioanalysis experts overseas as well. In addition, incorporating the topics highly desired by you, the participants, we are planning to have various sessions including Medium Molecules, Biomarkers, Immunogenicities, Antibody-Drug Conjugate (ADC), LIMS, Patient Centric Sampling and Basic Courses. We are also planning sessions that provide the latest information from peripheral perspectives, such as public-private joint research and JPMA's initiatives.
How about taking a break from your day-to-day job and sharing in three days of learning with your peers who share the same purpose? We hope that more people will participate and engage in lively discussions, and that this will be a place where we can learn a lot more. I am looking forward to seeing you in person.
Under the global spread of the COVID-19 pandemic, drugs, vaccines and test kits have been developed and many people have been saved. It is no exaggeration to say that it would not have been realized without the technology and development of bioanalysis. Bioanalysis will become increasingly important in order to deliver a variety of treatments and prophylaxis options to people around the world more quickly and we, and everyone involved in bioanalysis, will continue to take on challenges in order to respond to new modalities and development strategies.
In order to achieve our common purpose, we would like the symposium to be a place where people from various areas, such as government, academia, pharmaceutical companies, CROs, and device manufacturers can learn and collaborate together. That is why we decided the theme of the event will be "BRINGING TOGETHER ~ The Expertise of Bioanalysis". The JBF Steering Committee members are also working together for preparation of the symposium with our best ability to “bring together” the expertise, skills and experiences related to bioanalysis that are useful to you, to “bring together” people to be connected and also hopefully to "bring together" participants in a face-to-face symposium for providing a more meaningful time and participation.
The ICH M10 Guidelines reached Step 4 in May this year, and we have finally entered the implementation stage. In this event, we will set up an ICH M10 session and are planning that session can discuss a smoother implementation collaborating with bioanalysis experts overseas as well. In addition, incorporating the topics highly desired by you, the participants, we are planning to have various sessions including Medium Molecules, Biomarkers, Immunogenicities, Antibody-Drug Conjugate (ADC), LIMS, Patient Centric Sampling and Basic Courses. We are also planning sessions that provide the latest information from peripheral perspectives, such as public-private joint research and JPMA's initiatives.
How about taking a break from your day-to-day job and sharing in three days of learning with your peers who share the same purpose? We hope that more people will participate and engage in lively discussions, and that this will be a place where we can learn a lot more. I am looking forward to seeing you in person.
August 2022
14th JBF Symposium
Tomoko Arakawa, Executive Committee Chair
(Pfizer R&D Japan)
Yumi Nishiguchi, Executive Committee Vice Chair
(CMIC Pharma Science Co.,Ltd.)
14th JBF Symposium
Tomoko Arakawa, Executive Committee Chair
(Pfizer R&D Japan)
Yumi Nishiguchi, Executive Committee Vice Chair
(CMIC Pharma Science Co.,Ltd.)